RICHMOND, Virginia, ROSH HA'AYIN, Israel, June 16 /PRNewswire/ -- EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for advanced chronic wound management, recently announced the formation of its Scientific Advisory Board (SAB) comprised of world-renowned scientists, researchers and practitioners with diversified expertise in chronic wounds. The Company named David Armstrong, DPM PhD, Rob Kirsner, MD, PhD, Diane L. Krasner, PhD RN, FAAN, Joseph L. Mills, MD, PhD and Itzhak (Tzaki) Siev-Ner, MD as members of the SAB. David Armstrong will chair the Advisory Board. The SAB will meet regularly to provide EnzySurge with scientific and clinical guidance for its research, regulatory and commercialization activities.
"We are delighted with the caliber of scientists and practitioners who have decided to join our SAB said Amir Shiner, CEO of EnzySurge. "They are not only key opinion leaders in the various areas relevant to our field, but they also all bring industry experience, which will be instrumental as we move toward commercializing our products. The individual and collective expertise of our Scientific Advisory Board in diabetic foot, venous and pressure ulcers, biotechnology, clinical development and wound care standards of care, will no doubt accelerate our research and development and will ensure we address the most vital needs of our target market."
EnzySurge's DermaStream(TM) product line is based on its proprietary
Continuous Streaming Therapy (CST(TM)) technology. The comprehensive system
continuously streams a fresh supply of active solutions to a controlled
wound environment. EnzySurge has developed a series of bio-active
therapeutic solutions to facilitate safe and effective healing of chronic
wounds, from debridement, through regeneration to closure. The DermaStream
family of products is designed to treat all forms of chronic wounds
including diabetic ulcers, venous ulcers and pressure ulcers. DermaStream
|SOURCE EnzySurge Ltd|
Copyright©2008 PR Newswire.
All rights reserved